| Daclizumab: a potential asthma therapy? | |
| | |
MedLine Citation:
|
PMID: 20804450 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Airways inflammation in asthma is triggered and maintained by CD4+ (Th2) cells which are activated by IL-2 and stimulate the eosinophilic inflammation, IgE secretion and mucus hyperproduction. Current anti-inflammatory therapies include inhaled corticosteroids, and leukotriene modifiers but they are not universally effective. IL-2 pathway inhibition might represent a potent anti-inflammatory therapy in asthma given the cytokine early role in the asthma complex inflammatory cascade and daclizumab which is a IL-2R blocker currently used as an immunsupressor in organ transplantation might be a potential asthma therapy. This is review on the pathogenic role of IL-2, on the therapeutic potential of daclizumab and on its related patents. |
| | |
Authors:
|
Sabina A Antoniu |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Recent patents on inflammation & allergy drug discovery Volume: 4 ISSN: 1872-213X ISO Abbreviation: Recent Pat Inflamm Allergy Drug Discov Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-09-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101309297 Medline TA: Recent Pat Inflamm Allergy Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 214-21 Citation Subset: IM |
Affiliation:
|
Gr T Popa University of Medicine and Pharmacy Iaşi, Department of Medicine II -Pulmonary Disease, Pulmonary University Hospital, 30 Dr I Cihac Str, 700115 Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antagonism of eosinophil accumulation in asthma.
Next Document: Review article: stem cell therapies for inflammatory bowel disease - efficacy and safety.